![Doctor Discussion Guide](http://s1.studyres.com/store/data/017708127_1-91330855bb10354dc43fb15278762097-300x300.png)
Doctor Discussion Guide
... medicine are at an increased risk of death, compared to placebo (sugar pill). GEODON is not approved for treating these patients. GEODON may increase the risk of changes to your heart rhythm. You should not take GEODON if you have certain kinds of heart conditions that change your heart rhythm, a re ...
... medicine are at an increased risk of death, compared to placebo (sugar pill). GEODON is not approved for treating these patients. GEODON may increase the risk of changes to your heart rhythm. You should not take GEODON if you have certain kinds of heart conditions that change your heart rhythm, a re ...
LIPIDIL MICRO PM
... dose (MRHD) and in rabbits when given in doses 9 times the MRHD (on the basis of mg/m2 surface area). There are no adequate and well-controlled studies in pregnant women. Fenofibrate should not be used during pregnancy. (See CONTRAINDICATIONS). ...
... dose (MRHD) and in rabbits when given in doses 9 times the MRHD (on the basis of mg/m2 surface area). There are no adequate and well-controlled studies in pregnant women. Fenofibrate should not be used during pregnancy. (See CONTRAINDICATIONS). ...
avodart soft gelatin capsules
... In clinical trials, AVODART reduced serum PSA concentration by approximately 50% within 3 to 6 months of treatment. This decrease was predictable over the entire range of PSA values in subjects with symptomatic BPH, although it may vary in individuals. AVODART may also cause decreases in serum PSA i ...
... In clinical trials, AVODART reduced serum PSA concentration by approximately 50% within 3 to 6 months of treatment. This decrease was predictable over the entire range of PSA values in subjects with symptomatic BPH, although it may vary in individuals. AVODART may also cause decreases in serum PSA i ...
Wellbutrin - GSK Source
... Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (selective serotonin reuptake inhibitors [SSRIs] and others) show that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18 to 24) with MDD and ...
... Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (selective serotonin reuptake inhibitors [SSRIs] and others) show that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18 to 24) with MDD and ...
Guidelines for warfarin management in the community
... The risk of stroke should be weighed against the risk of bleeding to assess appropriateness of anticoagulant therapy. Warfarin causes major bleeding in one to two per cent of people treated and intracranial bleeding in 0.1 to 0.5 per cent of patients each year of treatment (Gallus et al. 2000). The ...
... The risk of stroke should be weighed against the risk of bleeding to assess appropriateness of anticoagulant therapy. Warfarin causes major bleeding in one to two per cent of people treated and intracranial bleeding in 0.1 to 0.5 per cent of patients each year of treatment (Gallus et al. 2000). The ...
Product Monograph
... Particular care should be exercised when administering NEXAVAR to patients who are suspected to be at an increased risk of experiencing torsade de pointes. Risk factors for torsade de pointes in the general population include, but are not limited to, the following: female gender; age 65 years or old ...
... Particular care should be exercised when administering NEXAVAR to patients who are suspected to be at an increased risk of experiencing torsade de pointes. Risk factors for torsade de pointes in the general population include, but are not limited to, the following: female gender; age 65 years or old ...
H alfLytely and B isacodyl Tablet B ow el P rep K it M e d ica tio n G
... Patients with impaired water handling who experience severe vomiting should be closely monitored including measurement of electrolytes (sodium, potassium, calcium, BUN and creatinine). Use caution when prescribing HalfLytely and Bisacodyl Tablet Bowel Prep Kit for patients with impaired renal functi ...
... Patients with impaired water handling who experience severe vomiting should be closely monitored including measurement of electrolytes (sodium, potassium, calcium, BUN and creatinine). Use caution when prescribing HalfLytely and Bisacodyl Tablet Bowel Prep Kit for patients with impaired renal functi ...
Product Information - Therapeutic Goods Administration
... Cmax, 3 to 5 hours after dosing with 250 mg of cobicistat. This finding was not considered to be clinically significant. In a thorough QT/QTc study in 126 healthy subjects, elvitegravir at therapeutic or supratherapeutic doses approximately 2 times the recommended therapeutic dose did not affect the ...
... Cmax, 3 to 5 hours after dosing with 250 mg of cobicistat. This finding was not considered to be clinically significant. In a thorough QT/QTc study in 126 healthy subjects, elvitegravir at therapeutic or supratherapeutic doses approximately 2 times the recommended therapeutic dose did not affect the ...
avodart - Urological Sciences Research Foundation
... 2-dihydrodutasteride metabolites are much less potent than dutasteride against both isoforms of human 5AR. The activity of 6β-hydroxydutasteride is comparable to that of dutasteride. Dutasteride and its metabolites were excreted mainly in feces. As a percent of dose, there was approximately 5% uncha ...
... 2-dihydrodutasteride metabolites are much less potent than dutasteride against both isoforms of human 5AR. The activity of 6β-hydroxydutasteride is comparable to that of dutasteride. Dutasteride and its metabolites were excreted mainly in feces. As a percent of dose, there was approximately 5% uncha ...
Depakote Sprinkle Capsules
... Depakote Sprinkle Capsules has not been systematically studied as initial therapy. Patients should initiate therapy at 10 to 15 mg/kg/day. The dosage should be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Ordinarily, optimal clinical response is achieved at daily doses below ...
... Depakote Sprinkle Capsules has not been systematically studied as initial therapy. Patients should initiate therapy at 10 to 15 mg/kg/day. The dosage should be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Ordinarily, optimal clinical response is achieved at daily doses below ...
Rapanofal Package Insert
... In dogs, the duration of anesthesia following the recommended induction dose (5.5 to 7.0 mg/kg without premedication) is generally 5 to 7 minutes. The duration of anesthesia after maintenance doses varies from 2 to 6 minutes following 1.1 mg/kg to 6 to 10 minutes following 3.3 mg/kg. Full standing r ...
... In dogs, the duration of anesthesia following the recommended induction dose (5.5 to 7.0 mg/kg without premedication) is generally 5 to 7 minutes. The duration of anesthesia after maintenance doses varies from 2 to 6 minutes following 1.1 mg/kg to 6 to 10 minutes following 3.3 mg/kg. Full standing r ...
Oral Cyclophosphamide Confounds the Relationship between
... systemic lupus erythematosus and can lead to chronic kidney disease or end stage renal failure [1, 2]. Clinical trials from ...
... systemic lupus erythematosus and can lead to chronic kidney disease or end stage renal failure [1, 2]. Clinical trials from ...
Diltiazem Hydrochloride Extended-Release Capsules, USP
... 300 mg of diltiazem hydrochloride in six normal volunteers, the average maximum PR prolongation was 14% with no instances of greater than first-degree AV block. Diltiazemassociated prolongation of the AH interval is not more pronounced in patients with first-degree heart block. In patients with sick ...
... 300 mg of diltiazem hydrochloride in six normal volunteers, the average maximum PR prolongation was 14% with no instances of greater than first-degree AV block. Diltiazemassociated prolongation of the AH interval is not more pronounced in patients with first-degree heart block. In patients with sick ...
Aust Dent J 2014. Protocol in Managing Oral Surgical Patients
... The univalent direct thrombin inhibitors such as ximelagatran and dabigatran reversibly bind only to the active site on the thrombin molecule, inhibiting both free and clot bound thrombin.8,9 Direct thrombin inhibitors also have an antiplatelet effect by reducing the thrombin mediated activation of ...
... The univalent direct thrombin inhibitors such as ximelagatran and dabigatran reversibly bind only to the active site on the thrombin molecule, inhibiting both free and clot bound thrombin.8,9 Direct thrombin inhibitors also have an antiplatelet effect by reducing the thrombin mediated activation of ...
Full Prescribing Information
... be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). ...
... be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). ...
Ketofol for bone marrow aspiration and lumbar puncture in Children
... cell count at the time of diagnosis have been identified who have a 5-year disease-free survival rate greater than 80%(3). With the rising number of long-term serious, increased attention has been directed towards possible long-term effects of leukemia and its treatment. Presently, most therapeutic ...
... cell count at the time of diagnosis have been identified who have a 5-year disease-free survival rate greater than 80%(3). With the rising number of long-term serious, increased attention has been directed towards possible long-term effects of leukemia and its treatment. Presently, most therapeutic ...
1. name of the medicinal product
... There was an increased reporting of lower respiratory tract infections (particularly pneumonia and bronchitis) in the TORCH study in patients with COPD receiving salmeterol/fluticasone propionate 50/500 micrograms twice daily compared with placebo as well as in studies SCO40043 and SCO100250 compari ...
... There was an increased reporting of lower respiratory tract infections (particularly pneumonia and bronchitis) in the TORCH study in patients with COPD receiving salmeterol/fluticasone propionate 50/500 micrograms twice daily compared with placebo as well as in studies SCO40043 and SCO100250 compari ...
Collagenase clostridium histolyticum
... on stability at ≤ -60°C in 5 mL polycarbonate vials filled to 1 mL. This trend was exacerbated by shipping the stability samples on dry ice to contract testing laboratories. The specifications for pH has been widen from 7.5-8.5 at release to 6.5-8.5 at end of shelf-life and appropriate data has been ...
... on stability at ≤ -60°C in 5 mL polycarbonate vials filled to 1 mL. This trend was exacerbated by shipping the stability samples on dry ice to contract testing laboratories. The specifications for pH has been widen from 7.5-8.5 at release to 6.5-8.5 at end of shelf-life and appropriate data has been ...
essential veterinary drugs
... Royal University of Bhutan College of Natural Resources Faculty of Animal Husbandry Lobesa: Punakha ...
... Royal University of Bhutan College of Natural Resources Faculty of Animal Husbandry Lobesa: Punakha ...
Product Monograph - Ask Novartis Pharma
... When 200 mg entacapone is administered together with levodopa/carbidopa, it increases the area under the curve (AUC) of levodopa by approximately 35% and the elimination half-life of levodopa is prolonged from 1.3 h to 2.4 h. In general, the average peak levodopa plasma concentration and the time of ...
... When 200 mg entacapone is administered together with levodopa/carbidopa, it increases the area under the curve (AUC) of levodopa by approximately 35% and the elimination half-life of levodopa is prolonged from 1.3 h to 2.4 h. In general, the average peak levodopa plasma concentration and the time of ...
PRODUCT MONOGRAPH PrZOLOFT® (sertraline hydrochloride) 25
... In clinical trials, sertraline was not associated with a persistent increase in absolute QT intervals. However, the QT effect was not systematically evaluated in a thorough QT study. Cases of QTc prolongation and Torsade de Pointes (TdP) have been reported during post-marketing use of sertraline, in ...
... In clinical trials, sertraline was not associated with a persistent increase in absolute QT intervals. However, the QT effect was not systematically evaluated in a thorough QT study. Cases of QTc prolongation and Torsade de Pointes (TdP) have been reported during post-marketing use of sertraline, in ...
BENZOX AC BAR PRESCRIBING INFORMATION Benzoyl Peroxide
... discontinue use and institute appropriate therapy. After reaction clears, treatment may often be resumed with less frequent application. These preparations should not be used in or near the eyes or on mucous membranes. Avoid contact with hair, fabrics or carpeting as benzoyl peroxide will cause blea ...
... discontinue use and institute appropriate therapy. After reaction clears, treatment may often be resumed with less frequent application. These preparations should not be used in or near the eyes or on mucous membranes. Avoid contact with hair, fabrics or carpeting as benzoyl peroxide will cause blea ...
Traveler`s Diarrhea - Division of General Internal Medicine
... to 55 percent of persons who travel from developed countries to developing countries are affected.1,2 A study3 of Americans visiting developing countries found that 46 percent acquired diarrhea. The classic definition of traveler’s diarrhea is three or more unformed stools in 24 hours with at least ...
... to 55 percent of persons who travel from developed countries to developing countries are affected.1,2 A study3 of Americans visiting developing countries found that 46 percent acquired diarrhea. The classic definition of traveler’s diarrhea is three or more unformed stools in 24 hours with at least ...
... Sweden. By using the three concentrations, and by varying the number of breaths from the nebulizer, a protocol was developed creating approximately half-log increments in the cumulated dose of allergen (7, 21, 71, 213, 710, 2,130 and 7,100 biological units). Baseline FEV1 was defined as the best of ...
evista - Eli Lilly Canada
... The safety of EVISTA (60 mg once daily) was assessed in a placebo-controlled multinational trial of 10,101 postmenopausal women (age range 55-92) with documented coronary heart disease (CHD) or multiple CHD risk factors. Median study drug exposure was 5.1 years for both treatment groups (see CLINICA ...
... The safety of EVISTA (60 mg once daily) was assessed in a placebo-controlled multinational trial of 10,101 postmenopausal women (age range 55-92) with documented coronary heart disease (CHD) or multiple CHD risk factors. Median study drug exposure was 5.1 years for both treatment groups (see CLINICA ...
Ofloxacin
Ofloxacin is a synthetic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone.Ofloxacin was first patented in 1982 (European Patent Daiichi) and received approval from the U.S. Food and Drug Administration (FDA) on December 28, 1990. Ofloxacin is sold under a wide variety of brand names as well as generic drug equivalents, for oral and intravenous administration. Ofloxacin is also available for topical use, as eye drops and ear drops (marketed as Ocuflox and Floxin Otic respectively in the United States and marketed as Optiflox, eylox respectively in Jordan and Saudi Arabia).Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its “mirror image” or enantiomer dextrofloxacin.Ofloxacin has been associated with adverse drug reactions, such as tendon damage (including spontaneous tendon ruptures) and peripheral neuropathy (which may be irreversible); tendon damage may manifest long after therapy had been completed, and, in severe cases, may result in lifelong disabilities.